Robert Alexander, PhD
Chief Executive Officer
Dr. Alexander has been involved in the formation and leadership of numerous biotechnology companies. Dr. Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. Prior to ZS Pharma, Dr. Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and Allakos. Prior to Alta Partners, Dr. Alexander was a Principal in MPM Capital’s BioEquities Fund. Robert joined MPM from Genentech, where he worked in the Business Development group.
Dr. Alexander is on the Board of Directors of Allena Pharmaceuticals. He holds a PhD from the University of North Carolina at Chapel Hill and a Bachelor of Science in Zoology from Miami University of Ohio.
CHIEF LEGAL OFFICER, GENERAL COUNSEL
Mr. Asbury has more than 20 years in the pharmaceutical industry at various size companies. Prior to Allakos, Mr. Asbury was General Counsel at Samsara BioCapital, a science-driven venture capital firm. From 2014 to 2016, Mr. Asbury was Chief Legal Officer and General Counsel at ZS Pharma (acquired by AstraZeneca) where he was responsible for all legal aspects of the organization, including intellectual property, SEC matters and strategic transactions. Prior to ZS Pharma, he was the Vice President and General Counsel of Pharmacyclics where he helped the company negotiate a $975 million deal with Johnson & Johnson for ibrutinib, its Phase 2 molecule. Prior to that, Mr. Asbury held a variety of positions at Genentech, most recently as Associate General Counsel and Senior Director of Transactional Law. Prior to joining Genentech, he worked for the law firm of Shearman & Sterling, where he specialized in corporate finance, mergers and acquisitions, and commercial debt financings.
Mr. Asbury has a BA in Soviet studies from Vanderbilt University and a JD from Stanford Law School.
Craig Paterson, MD
Chief Medical Officer
Dr. Paterson has more than 25 years of pharmaceutical, biotech experience, and clinical practice. Dr. Paterson has led numerous Clinical Development and Medical Affairs teams resulting in multiple NDAs, supplemental new drug applications (sNDAs), and biologic license applications (BLAs) in gastrointestinal diseases and other indications. Prior to joining Allakos, Dr. Paterson was the Lead Physician for Immunodermatology at UCB Pharma. He was also a co-founder and CMO of Vivelix Pharmaceuticals, Senior Vice President of Medical and Clinical Development at Salix Pharmaceuticals, and additionally, has held various positions of increasing responsibility at GlaxoSmithKline, King Pharmaceuticals and Endo International.
Dr. Paterson previously served as Chief, Colon and Rectal Surgery, Associate Professor of Surgery at University of Massachusetts Medical School and Assistant Professor of Surgery at McMaster University Medical Center. Dr. Paterson holds an MD and an MSc (physiology and pharmacology) from McMaster University, Ontario, Canada and an MBA from the University of Tennessee.
CHIEF FINANCIAL OFFICER
Mr. Radford has over 25 years of public company finance and leadership experience at companies in multiple industries and various stages of growth including providing financial operations leadership to commercial-stage companies. Prior to Allakos, as Senior Vice President of Finance at Aimmune Therapeutics, Mr. Radford was responsible for all aspects of strategic and operational finance activities supporting the launch of its first approved product, including financial planning, controllership, tax and treasury functions. Prior to working at Aimmune Therapeutics, he served as the Chief Financial Officer at HeartFlow, a medical technology company with commercial operations in the United States, Canada, Europe and Japan. Prior to joining HeartFlow, Mr. Radford served as Vice President of Finance at Intuitive Surgical, with responsibility for financial planning and analysis, investor relations and enterprise analytics. Prior to Intuitive Surgical, Mr. Radford held various positions at eBay, including Vice President of Finance for Marketplaces Europe, as well as Vice President, Corporate Controller, and Chief Accounting Officer. Mr. Radford began his career in the audit practice of PricewaterhouseCoopers.
Mr. Radford has a BBA from Ohio University.
Adam Tomasi, PhD
President and Chief Operating Officer
Prior to joining Allakos, Dr. Tomasi was Chief Scientific Officer and Head of Corporate Development at ZS Pharma where he led scientific, business development, and investor relation functions through the company’s initial public offering and sale to AstraZeneca. Before joining ZS Pharma, Dr. Tomasi was a Principal at Alta Partners where he contributed to investments in ZS Pharma (acquired by AstraZeneca), Lumena Pharmaceuticals (acquired by Shire), Excaliard (acquired by Pfizer), ChemGenex (acquired by Cephalon), Achaogen, Immune Design and Allakos. Dr. Tomasi served as a drug discovery scientist with Gilead Sciences and Cytokinetics.
Dr. Tomasi holds a Bachelor of Science in Chemistry from the University of California, Berkeley, an MBA from MIT and a PhD in Chemistry from the University of California, Irvine.
Chief Commercial Officer
Mr. Varacek has 30 years of experience in biopharmaceutical sales, account management, marketing and commercial operations leadership. Most recently, Mr. Varacek was the Senior Vice President, Sales and Commercial Operations at ZS Pharma (acquired by AstraZeneca). Prior to ZS Pharma, he held a variety of executive and management-level roles at InterMune (acquired by Roche AG), Affymax, Amgen and BMS. In his commercial leadership roles, Mr. Varacek has launch expertise with specialty, non-specialty, orphan disease products including both biologics and small molecule compounds.
Mr. Varacek has a Bachelor of Science in Biology from SUNY Binghamton.
Sally Bolmer, PhD, RAC
Senior Vice President, Regulatory Affairs and Drug Development
Dr. Bolmer has more than 25 years of experience in the biopharmaceutical industry. She was the Senior Vice President of Development and Regulatory Affairs at Human Genome Sciences with responsibility for formulation and implementation of global regulatory and drug development strategies. Prior to Human Genome Sciences, Dr. Bolmer held various scientific and leadership roles at Centocor including Executive Director for Regulatory Affairs. While at Centocor, she was responsible for preclinical, clinical and manufacturing strategy and submissions for INDs and Marketing Applications for Cardiovascular, Immunology, Oncology and Infectious disease products. During her career, she has secured approval for five first-in-class biologics, initiated INDs for over 50 indications, and submitted over 6 BLAs for products including murine, chimeric and human antibodies; radioconjugates; antibody fragments; and fusion proteins.
Dr. Bolmer received a Bachelor of Science in Biochemistry from Brown University and a PhD in Biological Chemistry from the Hershey Medical Center of Penn State University. She had a post-doctorate appointment at MIT in the Applied Biological Science and was an Assistant Research Professor at Mt. Sinai Medical Center in New York City studying glycoprotein synthesis.
Ruby Casareno, PhD
Senior Vice President, Technical Operations
Dr. Casareno has more than 17 years of biopharmaceutical experience in biologics process development, scale up, technology transfer, and contract manufacturing oversight. She contributed to 3 commercial and over 18 pre-clinical and clinical development programs. She was Director, Outsourced Manufacturing & Manufacturing Sciences and Technology at Portola Pharmaceuticals and led the biologics team in addressing BLA drug substance manufacturing-related regulatory questions. As Director of Process Development and Manufacturing at Oncomed Pharmaceuticals, she was responsible for biologics process development and ensuring GMP adherence for 9 clinical development programs. She held various scientific and leadership positions at Seattle Genetics, Maxygen, Johnson and Johnson (Scios), Xoma and Bio-Rad Laboratories.
Dr. Casareno has a Bachelor of Science in Chemistry from the University of the Philippines and received her PhD in Chemistry from The Ohio State University. She completed postdoctoral trainings at Washington University Medical School and at the University of California, San Francisco.